TSPAN32 and chronic myelogenous leukemia, BCR-ABL1 positive: During disease progression, genetic or epigenetic dysregulation might lead to insufficient expression of TAL1 or TSPAN32, resulting in TKI resistance or a poor response.46,47 Thus, with further studies the targeting of the TSPAN32 regulatory network may be utilized to promote TKI response during CML treatment.